Publication | Closed Access

Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass

Bone DiseaseZoledronic AcidBone HealthRapid OnsetClinical TrialsLow Bone MassMenopausePharmacotherapyBone DensityMedicineOsteoporosisBone MetabolismRheumatoid ArthritisWomen's HealthHealth Sciences